Business
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
-- Mr. Johnson brings 30 years of commercial experience to Caribou as company’s pipeline of genome-edited cell therapies advances -- BERKELEY, Calif., May 11,
About this update from Caribou Biosciences, Inc.
[{"type":"text","content":"-- Mr. Johnson brings 30 years of commercial experience to Caribou as company’s pipeline of genome-edited cell therapies advances --\nBERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical industry. “David has an impressive record of successfully building commercial infrastructure and launching new medicines for patients,” said Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer. “We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build our company and advance our pipeline of chRDNA-edited allogeneic cell therapies for patients with hematologic and solid tumors.” “Caribou is making its mark as a leader in the allogeneic cell therapy field, deploying its differentiated chRDNA technology to create off-the-shelf cell therapies that may reach greater numbers of patients globally than autologous cell therapies,” said Mr. Johnson. “I look forward to working with the Caribou leadership team and other board members as the company develops and advances its pipeline.” Mr. Johnson currently serves as chief commercial officer of Global Blood Therapeutics where he leads the global commercial functions that he built and which facilitated the launch of Oxbryta® in 2019. Previously, Mr. Johnson spent 15 years at Gilead Sciences, Inc., where he held roles of increasing responsibility in the company’s commercial organization. He was instrumental in the commercial launch of Gilead’s hepatitis C treatments Sovaldi®, Harvoni®, Epclusa®, and Vosevi®, and its hepatitis B treatment Vemlidy®. As vice president, sales and marketing, for Gilead’s Antiviral Business Unit, he launched the HIV treatments Complera® and Stribild®. Before Gilead, Mr. Johnson had an 11-year tenure at Glaxo Smith Kline, where he held various positions in sales, product marketing, business development, global commercial strategy, and portfolio development. Mr. Johnson earned an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina and a B.A. in business mark...